{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:39:47Z","timestamp":1789713587828,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s11914-008-0003-y","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T21:08:02Z","timestamp":1206738482000},"page":"12-16","source":"Crossref","is-referenced-by-count":56,"title":["Safety of parathyroid hormone for the treatment of osteoporosis"],"prefix":"10.1007","volume":"6","author":[{"given":"Paul D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,29]]},"reference":[{"key":"3_CR1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"R.M. Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434\u20131441.","journal-title":"N Engl J Med"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"E.S. Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9\u201317.","journal-title":"J Bone Miner Res"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"K.G. Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028\u20132039.","journal-title":"N Engl J Med"},{"issue":"Suppl1","key":"3_CR4","first-page":"S56","volume":"20","author":"S.L. Greenspan","year":"2005","unstructured":"Greenspan SL, Bone HG, Macciott TB, et al.: Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): results from the TOP study. J Bone Miner Res 2005, 20(Suppl 1):S56.","journal-title":"J Bone Miner Res"},{"key":"3_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4158\/EP.10.2.139","volume":"10","author":"P.D. Miller","year":"2004","unstructured":"Miller PD, Bilezikian JP, Deal C, Harris ST: Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004, 10:139\u2013148.","journal-title":"Endocr Pract"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"A.B. Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688\u2013703.","journal-title":"Endocr Rev"},{"key":"3_CR7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1359\/JBMR.051023","volume":"21","author":"A.H. Tashjian","year":"2006","unstructured":"Tashjian AH, Gagel RF: Teriparatide (human parathyroid hormone 1-34): two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006, 21:354\u2013365.","journal-title":"J Bone Miner Res"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00198-005-1915-3","volume":"17","author":"P.D. Miller","year":"2006","unstructured":"Miller PD, Silverman S, Gold DT, et al.: Rationale, objectives, and design of the Direct Analysis of Nonvertebral fracture in the Community Experience (DANCE) study. Osteoporos Int 2006, 17:85\u201390.","journal-title":"Osteoporos Int"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/BMM:4:1:1","volume":"4","author":"R. Wagman","year":"2006","unstructured":"Wagman R, Miller PD: The use of teriparatide and PTH (1-84) for the treatment of osteoporosis. Clin Rev Bone Mineral Metab 2006, 4:1\u201313.","journal-title":"Clin Rev Bone Mineral Metab"},{"key":"3_CR10","first-page":"1556","volume":"32","author":"P.D. Miller","year":"2005","unstructured":"Miller PD, Shergy WJ, Body JJ, et al.: Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005, 32:1556\u20131562.","journal-title":"J Rheumatol"},{"key":"3_CR11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1185\/030079905X49671","volume":"21","author":"H.K. Genant","year":"2005","unstructured":"Genant HK, Halse J, Briney WG, et al.: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005, 21:1027\u20131034.","journal-title":"Curr Med Res Opin"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00198-005-2013-2","volume":"17","author":"M.C. Nevitt","year":"2006","unstructured":"Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273\u2013280.","journal-title":"Osteoporos Int"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E. Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905\u2013916.","journal-title":"N Engl J Med"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","volume":"165","author":"M. McClung","year":"2005","unstructured":"McClung M, San Martin J, Miller PD, et al.: Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005, 165:1762\u20131768.","journal-title":"Arch Intern Med"},{"key":"3_CR15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","volume":"21","author":"P. Chen","year":"2006","unstructured":"Chen P, Miller PD, Delmas PD, et al.: Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785\u20131790.","journal-title":"J Bone Miner Res"},{"key":"3_CR16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P. Chen","year":"2005","unstructured":"Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal osteoporosis. J Bone Miner Res 2005, 20:962\u2013970.","journal-title":"J Bone Miner Res"},{"key":"3_CR17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P. Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker RR, et al.: Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 2007, 22:1173\u20131180.","journal-title":"J Bone Miner Res"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"D.W. Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland AS, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846\u20131853.","journal-title":"J Bone Miner Res"},{"key":"3_CR19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y. Jiang","year":"2003","unstructured":"Jiang Y, Zhao J, Mitlak BH, et al.: Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932\u20131941.","journal-title":"J Bone Miner Res"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"J.R. Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1\u201334)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539\u2013543.","journal-title":"J Bone Miner Res"},{"key":"3_CR21","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H. Dobnig","year":"2005","unstructured":"Dobnig H, Sipos AA, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970\u20133977.","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR22","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1359\/jbmr.2002.17.10.1741","volume":"17","author":"A.M. Parfitt","year":"2002","unstructured":"Parfitt AM: Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741\u20131743.","journal-title":"J Bone Miner Res"},{"key":"3_CR23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/B978-012098651-4\/50016-X","volume-title":"The Parathyroids: Basic and Clinical Concepts","author":"F.R. Bringhurst","year":"2001","unstructured":"Bringhurst FR: Physiologic actions of PTH and PTHRP: II. Renal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:227\u2013244."},{"key":"3_CR24","first-page":"213","volume-title":"The Parathyroids: Basic and Clinical Concepts","author":"G.J. Strewler","year":"2001","unstructured":"Strewler GJ: Physiologic actions of PTH and PTHrP: I. Skeletal actions. In The Parathyroids: Basic and Clinical Concepts. Edited by Bilizikian JP, Marcus R, Levine MA. New York: Academic Press; 2001:213\u2013226."},{"key":"3_CR25","first-page":"230","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"J.P. Bilezikian","year":"2006","unstructured":"Bilezikian JP, Silverberg SJ: Primary hyperparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 5. Edited by Favus MJ. Washington, DC: American Society for Bone and Mineral Research; 2006:230\u2013235.","edition":"5"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","volume":"333","author":"K.A. Hruska","year":"1995","unstructured":"Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995, 333:166\u2013172.","journal-title":"N Engl J Med"},{"key":"3_CR27","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E. Slatopolsky","year":"1999","unstructured":"Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14\u2013S19.","journal-title":"Kidney Int Suppl"},{"key":"3_CR28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"M. Holick","year":"2007","unstructured":"Holick M: Vitamin D deficiency. N Engl J Med 2007, 357:266\u2013281.","journal-title":"N Engl J Med"},{"key":"3_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2005.06.020","volume":"97","author":"R.P. Heaney","year":"2005","unstructured":"Heaney RP: The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005, 97:13\u201319.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(82)90567-8","volume":"72","author":"F.L. Coe","year":"1982","unstructured":"Coe FL, Favus MJ, Crockett T, et al.: Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 1982, 72:25\u201332.","journal-title":"Am J Med"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s001980050110","volume":"9","author":"R.P. Heaney","year":"1999","unstructured":"Heaney RP, Recker RR, Ryan RA: Urinary calcium in perimenopausal women: normative values. Osteoporos Int 1999, 9:13\u201318.","journal-title":"Osteoporos Int"},{"key":"3_CR32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1681\/ASN.V95917","volume":"9","author":"D.A. Bushinsky","year":"1998","unstructured":"Bushinsky DA: Nephrolithiasis. J Am Soc Nephrol 1998, 9:917\u2013924.","journal-title":"J Am Soc Nephrol"},{"key":"3_CR33","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.2006-2439","volume":"92","author":"P.D. Miller","year":"2007","unstructured":"Miller PD, Bilezikian JP, Diaz-Curiel M, et al.: Occurrence of hypercalciuria in patients treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535\u20133541.","journal-title":"J Clin Endocrinol Metab"},{"key":"3_CR34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"J.L. Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312\u2013321.","journal-title":"Toxicol Pathol"},{"key":"3_CR35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"J.L. Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Ma YL, Sato M: Bone neoplasms in F344 rats given teriparatide [rhPTH (1\u201334)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426\u2013438.","journal-title":"Toxicol Pathol"},{"issue":"Suppl1","key":"3_CR36","first-page":"S98","volume":"19","author":"C.E. Wilker","year":"2004","unstructured":"Wilker CE, Jolette J, Smith SY, et al.: No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1-84) for 2 years: role of the c-terminal PTH receptor? J Bone Miner Res 2004, 19(Suppl 1):S98.","journal-title":"J Bone Miner Res"},{"key":"3_CR37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","volume":"22","author":"K. Harper","year":"2007","unstructured":"Harper K, Krege JH, Marcus R, Mitlak BH: Osteosarcoma and teriparatide? J Bone Miner Res 2007, 22:334.","journal-title":"J Bone Miner Res"},{"key":"3_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","volume":"459","author":"T.A. Damron","year":"2007","unstructured":"Damron TA, Ward WG, Stewart A: Osteosarcoma, chondrosarcoma, and Ewing\u2019s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007, 459:40\u201347.","journal-title":"Clin Orthop Relat Res"},{"key":"3_CR39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1302\/0301-620X.89B6.18729","volume":"89","author":"S. Kalra","year":"2007","unstructured":"Kalra S, Grimer RJ, Spooner D, et al.: Radiation-induced sarcoma of bone: factors that determine outcome. J Bone Joint Surg Br 2007, 89:808\u2013813.","journal-title":"J Bone Joint Surg Br"},{"key":"3_CR40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0360-3016(91)90783-Z","volume":"21","author":"A. Taghian","year":"1991","unstructured":"Taghian A, de Vathaire F, Terrier P, et al.: Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991, 21:361\u2013367.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3_CR41","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.21223","volume":"104","author":"Y.M. Kirova","year":"2005","unstructured":"Kirova YM, Vilcoq JR, Asselain B, et al.: Radiationinduced sarcomas after radiotherapy for breast carcinoma: a large-scale, single institution review. Cancer 2005, 104:856\u2013863.","journal-title":"Cancer"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-008-0003-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-008-0003-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-008-0003-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T18:05:07Z","timestamp":1630951507000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-008-0003-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11914-008-0003-y","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}